In 2023, the global immunohistochemistry market revenue is estimated at $3.2 billion, with a projected growth to $4.7 billion by 2028, representing a CAGR of 7.4% from 2023 to 2028. This market analysis delves into industry trends, pricing, patents, key stakeholders, and consumer behavior. The market’s growth is driven by factors such as the aging population, increasing cancer prevalence, advanced IHC technology, reimbursement availability, and digital pathology adoption. Nonetheless, market growth is hindered by alternative technologies and industry consolidation, along with stringent regulatory requirements and a lack of standardization.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121632939
Kits Segment Leads Growth: In 2022, the kits segment experienced the highest growth rate in the immunohistochemistry market. This surge is attributed to the demand for comprehensive solutions from a single, dependable provider. Ready-to-use kits simplify the IHC process and are increasingly favored by diagnostic labs, hospitals, and research institutes.
Forensics Application Segment: Within the market’s application segments, forensics accounted for the smallest share in 2022. Although IHC plays a role in determining causes of death in forensics, its applications are primarily limited to identifying natural diseases due to tissue degradation when post-mortem analysis is delayed.
Key Market Players: The global immunohistochemistry market is highly competitive, with key players including F. Hoffmann-La Roche AG, Danaher Corporation, and Agilent Technologies, Inc. These players are expanding their presence through strategic partnerships, product launches, and approvals.
- F. Hoffmann-La Roche AG (Roche): Roche operates in the IHC market through its Pathology Lab segment, offering products like BenchMark ULTRA IHC/ISH System and OptiView DAB IHC Detection Kit (OptiView). Roche’s contribution to the IHC market has made it a prominent player.
- Danaher Corporation: Danaher, a global science and technology company, provides IHC products through its subsidiary, Leica Biosystems. Their focus on technology-enabled solutions, R&D investments, and comprehensive product lines is driving their market share growth.
Request Free Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=121632939
Driver: Adoption of Digital Pathology Fueling Market Growth
Digital pathology systems are increasingly being utilized by healthcare professionals across the globe due to the ongoing trend of automation of diagnostic laboratory processes across major healthcare markets. Digital immunohistochemistry (IHC) integrates traditional IHC staining with digital imaging and analysis tools, facilitating the conversion of stained tissue slides into electronic images that can be remotely accessed, analyzed, and stored, eliminating the reliance on physical slides and enabling efficient collaboration among pathologists and researchers. The advantages of digital pathology application in IHC is that it eliminates physical slide handling and storage, facilitates remote collaboration among pathologists for case sharing and second opinions, enables objective and standardized quantitative analysis of staining, and allows efficient archiving and integration of digital images with other data for comprehensive analysis and research. The major players offering digital IHC are F. Hoffmann-La Roche AG, Leica Biosystems (Danaher Corporation), and Agilent Technologies.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com
